Tishtha 40mg Injection contains the active ingredient Nivolumab. It is used to treat various cancers, including those of the skin, lungs, kidneys, lymph nodes, bladder, oesophagus, and urinary tract. This medication is recommended when cancer has returned after previous treatments such as medication, surgery, and radiation. It aids the immune system in combating cancer more effectively.
The drug functions by targeting and inhibiting specific molecules that may suppress or diminish the immune system’s capacity to identify and attack cancer cells. By blocking these molecules, it enhances the immune response against cancer, potentially leading to the reduction or slowing of tumour growth.
One of the advantages of Tishtha and other immunotherapy agents is their ability to elicit long-lasting responses in some patients, even after treatment has ceased. This is in contrast to conventional chemotherapy and radiation therapy, which generally offer only temporary relief and may cause significant side effects. It is not recommended for patients who have experienced a severe allergic reaction to the drug or its components.
Tishtha Injection is also not suitable for individuals with certain autoimmune diseases, such as lupus or rheumatoid arthritis, as the medication may further activate the immune system and worsen these conditions. Furthermore, it should be administered with caution to patients who have a history of organ transplants.